Search Results
Your search for ASCO Post matches 17390 pages
Showing 11251 - 11300SGO 2017: New Immunotherapy Axalimogene Filoslisbac Shows Positive Results in Cervical Cancer
A new immunotherapy drug, axalimogene filoslisbac (AXAL), showed improved survival rates for patients with cervical cancer, according to a study presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Study coauthor Charles Leath, MD, MSPH, an SGO member ...
SGO 2017: Secondary Endpoint Results of Phase III ENGOT-OV16/NOVA Trial of Niraparib in Recurrent Ovarian Cancer
Secondary endpoint results from the phase III ENGOT-OV16/NOVA trial of niraparib were presented at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, by Sven Mahner, MD, Director, Department of Gynecology and Obstetrics, University of Munich. “The results of...
FDA Approves Pembrolizumab for Relapsed or Refractory Classical Hodgkin Lymphoma in Adult and Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of adult and pediatric patients who have refractory classical Hodgkin lymphoma or have relapsed after three or more prior lines of...
Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care
A new study demonstrates that the use of less radiation therapy for patients with breast cancer who have undergone lumpectomy does not negatively impact patient outcomes, and could result in significant reductions in health-care costs. These findings, which examine patient eligibility for...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
FDA Approves Ribociclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On March 13, 2017, the U.S. Food and Drug Administration (FDA) approved ribociclib (Kisqali), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive,...
ACC.17: History of Exercise Helps Prevent Heart Disease After Breast Cancer
Regular exercise appears to help mitigate the increased cardiovascular risk faced by women treated for breast cancer, according to a study scheduled for presentation at the American College of Cardiology's 66th Annual Scientific Session (ACC.17). The study found that women with breast cancer who...
Key Gene Controlling Tumor Growth in Gliomas Pinpointed
Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings, published by Edwards et al in Nature Scientific Reports, could move physicians closer to their...
Low-Grade Gliomas: Understanding the New Treatment Paradigm
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed, as detailed in a recent review in the Journal of Oncology Practice.1 The...
Alice T. Shaw, MD, PhD, and Pasi A. Jänne, MD, PhD, Named Co‑Leaders of SU2C-ACS Dream Team on Lung Cancer
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital Cancer Center, and Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, have been named co-leaders of the Stand Up to Cancer (SU2C)-American Cancer Society (ACS) Lung Cancer Dream Team, joining co-leader Jedd Wolchok, MD, PhD, of...
Royal Swedish Academy of Sciences Inaugural Sjöberg Prize Awarded to James P. Allison, PhD, and Tony Hunter, PhD
The Royal Swedish Academy of Sciences (RSAS) has decided to award the inaugural Sjöberg Prize 2017 to James P. Allison, PhD, Professor and Vivian L. Smith Distinguished Chair in Immunology at The University of Texas MD Anderson Cancer Center, and Tony Hunter, PhD, American Cancer Society...
Close to Home: Dr. Rick Boulay’s Experience With Cancer Survivorship and Caregiving
Richard ‘Rick’ Boulay, MDChief of Gynecologic Oncology Institution: Lehigh Valley Health Network Member since: 2016 Three years ago, Richard ‘Rick’ Boulay, MD, Chief of Gynecologic Oncology at Lehigh Valley Health Network, walked onto the stage at TEDx Lehigh River and confronted his audience...
Study Identifies How Cancer Cells May Develop Resistance to FGFR Inhibitors
A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC– James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth...
Ronald A. DePinho, MD, to Resign as President of MD Anderson
Ronald A. DePinho, MD, President of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven of the University of Texas System tendering his resignation. Chancellor McRaven has asked Dr. DePinho to stay on through the end of the Texas Legislative...
Scripps Florida Collaboration Awarded $3.3 Million to Develop Next-Generation Breast Cancer Therapies
A pair of scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded up to $3.3 million from the National Cancer Institute of the National Institutes of Health (NIH) to create the next generation of breast cancer treatments for the thousands of patients whose...
Expect Questions About the Cervical Cancer Mortality Study
A widely reported study found that cervical cancer mortality was higher and the racial disparity between black and white women greater than previously reported.1 The study omitted from the mortality estimates those women who had undergone hysterectomies, usually involving removal of the cervix....
Honoring the Life of Nancy E. Armitage
The University of Nebraska community mourns the loss of dedicated community leader and volunteer Nancy E. Armitage of Omaha. She died February 27, 2017, from complications associated with pancreatic cancer. Nancy is remembered for the support and encouragement she offered to others over the years...
Cervical Cancer Mortality Is Higher and Racial Disparity Wider Than Previously Reported
Cervical cancer mortality rates were significantly higher, particularly among black women, when national data were corrected to exclude women who have had hysterectomies. For black women, the cervical cancer mortality rate rose from 5.7 to 10.1 per 100,000 when corrected for hysterectomy, an...
2017 Oncology Meetings
MARCH ESMO Symposium on Signaling Pathways in Cancer 2017March 17-18 • Barcelona, SpainFor more information: http://esmo.org/Conferences/Signalling-Pathways-2017 17th Multidisciplinary Management of Cancers: A Case-Based ApproachMarch 17-19 • Napa, CaliforniaFor more...
Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
Immunotherapy has been a major advance in lung cancer, but it is not without its challenges, according to Sanjay Popat, PhD, FRCP, a consultant medical oncologist and reader in cancer medicine at the Royal Marsden Hospital, London, UK. He reviewed some of the challenges pertaining to the use of...
Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer
As reported by Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, Temple Health, and colleagues in The Lancet Oncology, pembrolizumab (Keytruda) has shown activity in patients in the locally advanced or metastatic urothelial carcinoma cohort included in the phase Ib KEYNOTE-012 trial. In the...
Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer
In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. Heather Hampel, MS, CGC, of The Ohio State University Comprehensive Cancer Center,...
Potential Biomarker of Recurrent Venous Thromboembolism in Patients Receiving Anticoagulants
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Alok A. Khorana, MD, of the Cleveland Clinic, and colleagues found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on ...
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10-mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. Clinical Trial Findings The...
Eric D. Tetzlaff, MHS, PA-C, Receives National Recognition as AAPA Distinguished Fellow
Eric D. Tetzlaff, MHS, PA-C, a physician assistant at Fox Chase Cancer Center, has been recognized as a Distinguished Fellow of the American Academy of Physician Assistants (AAPA). He practices clinical care for patients with gastrointestinal cancers and sarcomas and has been at Fox Chase for most ...
An Oncologist’s Straightforward Guide for Women With Breast Cancer
If you Google the search term “breast cancer,” about 155,000,000 results will pop up in .83 seconds. Add to that pamphlets, journal articles, and library shelves bending under the weight of books written about breast cancer. That’s a mind-bending amount of information to parse through for the...
ASCO and NCCN to Collaborate on Guidelines on Management of Immunotherapy Side Effects
ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy. This novel collaboration aims to rapidly support improved quality of care for the growing number of...
Cleveland Clinic Opens New Taussig Cancer Center
The new Cleveland Clinic Taussig Cancer Center began welcoming patients on March 6, 2017. The 377,000 square-foot facility houses all outpatient cancer treatment services in one location, with the center’s team of medical and radiation oncologists, surgeons, nurses, genetic counselors, social...
IASLC Statement Regarding Philip Morris’ Smoke-Free Future
On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement: According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, [IASLC] views with some skepticism Philip Morris’ recent statement...
CAR T-Cell Therapy Emerging in Multiple Myeloma
For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven...
New NCCN Treatment Guides to Help Patients With Waldenström’s Macroglobulinemia Make Informed Care Decisions
Waldenström’s macroglobulinemia, a rare subtype of non-Hodgkin lymphoma, affects approximately 1,500 to 2,000 people in the United States each year. Although it is not curable, Waldenström’s macroglobulinemia is grow slowly, and in many patients, it is manageable as a chronic disease. To that end,...
Fox Chase–Temple University Hospital Bone Marrow Transplant Program Awarded FACT Accreditation
The Fox Chase–Temple University Hospital Bone Marrow Transplant Program has received internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center. By demonstrating compliance with the FACT-JACIE...
Sandra J. Horning, MD, Received Duane Roth Memorial Award
Sandra J. Horning, MD, Chief Medical Officer and Executive Vice President of Global Development for Roche/Genentech, was named the 2017 recipient of the Duane Roth Memorial Award. The award was presented February 16 at the annual Industry/Academia Translational Oncology Symposium at the University ...
Study Finds No Evidence of Cytomegalovirus in Glioblastoma and Other High-Grade Gliomas
In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins said they have found no evidence of cytomegalovirus (CMV) infection and concluded that a link between the two diseases, as claimed by earlier reports, likely does not exist. A ...
Expert Point of View: Allyson J. Ocean, MD
Allyson J. Ocean, MD, a pancreatic cancer specialist at New York-Presbyterian Hospital/Weill Cornell Medical Center and Associate Professor of Medicine at the Weill Medical College of Cornell University, commented on these study findings. “While I applaud the authors for the data presented, the...
No Benefit From Older Standard-of-Care Drug in Adjuvant Chemotherapy for High-Risk Prostate Cancer, but Newer Trials Feasible
An older trial designed to evaluate the benefits of adjuvant therapy following radical prostatectomy in patients with high-risk prostate cancer showed no difference in overall or disease-free survival between 2 years of androgen-deprivation therapy and 2 years of androgen-deprivation therapy plus...
How Stupid Cancer Is Building a Support Community for AYA Survivors
In 1995, Matthew Zachary, an aspiring concert pianist and composer, was en route to graduate school to study film composition when he lost all fine-motor coordination in his left hand, was diagnosed with pediatric brain cancer (medulloblastoma), told he would never play again, and was given 6...
FALCON Trial Informs the Evolving Role of Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Endocrine therapy for breast cancer has evolved over the years. Initial endocrine therapies consisted of ablative procedures (oophorectomy, adrenalectomy, and hypophysectomy). With the availability of pharmaceutical estrogens, progestins, and androgens, ablative procedure utilization begin to...
ASCO Quality Care 2017: Reducing Overuse of Colony-Stimulating Factors in Febrile Neutropenia Without Compromising Patient Safety
In a retrospective cohort study, Adeboyeje et al found that a utilization management tool that makes real-time care recommendations can help reduce overuse of substances that assist the bone marrow in producing blood cells, called colony-stimulating factors, in attempts to prevent fevers in...
ASCO Quality Care 2017: Cost and Survival Analysis Before and After Implementation of Clinical Pathways for Patients With Stage IV NSCLC
In a study reported at the 2017 Quality Care Symposium by Zheng et al (Abstract 3) and published in the Journal of Oncology Practice by Jackman et al, researchers explored the use of clinical pathways to support clinical decision-making and manage resources for patients with late-stage...
ASCO Quality Care 2017: Reduction in Chemotherapy Errors Through Improvement Science
The majority of children with cancer are treated with complicated chemotherapy regimens that include multiple drugs, demanding monitoring schedules and complex dosing based on body surface area that often require changes in dose. Given this high risk for error in treating children with these highly ...
Brian Weiss, MD, on Reducing Treatment Errors With Improvement Science
Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).
Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)
Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival...
Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices
Gabrielle Rocque, MD, of the University of Alabama at Birmingham, discusses the challenges of implementing Oncology Care Model requirements, such as providing treatment plans, and the opportunities to transform practices with improved workflow and patient outcomes.
Gwendolyn P. Quinn, PhD, on Underserved Cancer Patients and Survivors: Are We Listening to Them?
Gwendolyn P. Quinn, PhD, of Moffitt Cancer Center, discusses the challenges that minority, LGBTQ, low-literacy, and underserved populations face in getting their voices heard and what it will take to change that.
Julie Bryar Porter, MS, on Improving Care: One Center’s Experience
Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).
Blase N. Polite, MD, MPP: The Oncology Care Model in Academia
Blase N. Polite, MD, MPP, of the University of Chicago, discusses implementing the Oncology Care Model in an academic health center and the challenges of getting buy-in from faculty members.
Laura E. Panattoni, PhD, on Costs of Preventable Emergency Department Use
Laura E. Panattoni, PhD, of the Fred Hutchinson Cancer Research Center, discusses results from a regional study on emergency department costs during cancer treatment and the need to focus on managing symptoms (Abstract 2).
Nicole Mittmann, PhD, on Breast Cancer Well Follow-up
Nicole Mittmann, PhD, of the Sunnybrook Health Sciences Centre, discusses her study findings on transitioning breast cancer survivors to primary care and the savings in resources and dollars that accrued as a result (Abstract 1).
Robert S. Miller, MD, on CancerLinQ: Big Data and Clinical Effectiveness
Robert S. Miller, MD, of ASCO, updates the progress of CancerLinQ and its data set, now being used by oncologists to track quality measurement and reporting.
